首页 > 最新文献

British Journal of Pharmacy最新文献

英文 中文
Case Law: A Review of Selected Pharmaceutical Patents Litigated in the UK Courts during 2022 判例法:2022 年英国法院诉讼的部分药品专利回顾
Pub Date : 2023-12-31 DOI: 10.5920/bjpharm.1346
Sarah-Jane Crawford, H. O'Brien, J. A. Stones
Patents lie at the interface between technology and law.  This review provides a summary of four high profile cases from 2022 in which patents in the pharmaceutical or medical space were litigated in the UK Courts.  The first case concerns Astellas’ patent for Betmiga® (mirabegron) for overactive bladder.  The second case involves a patent to Bristol-Meyers Squibb for Eliquis® (apixaban) for thromboembolic disorders.  The third case concerns Novartis’ patent for Exjade® (deferasirox) for use in the treatment of conditions involving excess iron in the blood caused by haemochromatosis, etc.  In the final case, Novartis defended its patent for Gilenya® (fingolimod) as a disease modifying therapy for relapsing remitting multiple sclerosis.  The article aims to focus on the technology behind the patents and to provide an insight into how science interacts with law in the context of patent enforcement and infringement.
专利处于技术与法律的交界处。 本综述概述了 2022 年英国法院审理的四起备受关注的制药或医疗领域专利诉讼案件。 第一起案件涉及安斯泰来公司(Astellas)治疗膀胱过度活动症的 Betmiga® (米贝琼)专利。 第二起案件涉及 Bristol-Meyers Squibb 公司治疗血栓栓塞性疾病的 Eliquis® (阿哌沙班)专利。 第三个案例涉及诺华公司(Novartis)的 Exjade® (地拉罗司)专利,该专利用于治疗血色素沉着病等引起的血液中铁含量过高的疾病。 在最后一个案例中,诺华公司为其 Gilenya® (芬戈莫德)作为复发性缓解型多发性硬化症疾病调整疗法的专利进行了辩护。 文章旨在重点介绍专利背后的技术,并深入探讨在专利实施和侵权的背景下科学如何与法律相互作用。
{"title":"Case Law: A Review of Selected Pharmaceutical Patents Litigated in the UK Courts during 2022","authors":"Sarah-Jane Crawford, H. O'Brien, J. A. Stones","doi":"10.5920/bjpharm.1346","DOIUrl":"https://doi.org/10.5920/bjpharm.1346","url":null,"abstract":"Patents lie at the interface between technology and law.  This review provides a summary of four high profile cases from 2022 in which patents in the pharmaceutical or medical space were litigated in the UK Courts.  The first case concerns Astellas’ patent for Betmiga® (mirabegron) for overactive bladder.  The second case involves a patent to Bristol-Meyers Squibb for Eliquis® (apixaban) for thromboembolic disorders.  The third case concerns Novartis’ patent for Exjade® (deferasirox) for use in the treatment of conditions involving excess iron in the blood caused by haemochromatosis, etc.  In the final case, Novartis defended its patent for Gilenya® (fingolimod) as a disease modifying therapy for relapsing remitting multiple sclerosis.  The article aims to focus on the technology behind the patents and to provide an insight into how science interacts with law in the context of patent enforcement and infringement.","PeriodicalId":9253,"journal":{"name":"British Journal of Pharmacy","volume":"98 24","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139131835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ensuring Pharmaceutical Product Success through Excipient QbD Efforts 通过辅料QbD的努力确保药品的成功
Pub Date : 2022-10-24 DOI: 10.5920/bjpharm.1243
M. S. Qadir
It isessential to understand excipients’ critical material attributes. A QbDstrategy that includes historical data analysis and experimental work has beenused in functional excipients such as Hypromellose (HPMC) to develop thisunderstanding. The use of multivariate analysis helped to identify excipientvariability and the support it could provide to improve the final product robustness.
了解辅料的关键物质属性是至关重要的。包括历史数据分析和实验工作的qbd策略已用于功能性辅料,如羟丙基纤维素(HPMC),以发展这种理解。多变量分析的使用有助于确定辅料的可变性,并为提高最终产品的稳健性提供支持。
{"title":"Ensuring Pharmaceutical Product Success through Excipient QbD Efforts","authors":"M. S. Qadir","doi":"10.5920/bjpharm.1243","DOIUrl":"https://doi.org/10.5920/bjpharm.1243","url":null,"abstract":"It isessential to understand excipients’ critical material attributes. A QbDstrategy that includes historical data analysis and experimental work has beenused in functional excipients such as Hypromellose (HPMC) to develop thisunderstanding. The use of multivariate analysis helped to identify excipientvariability and the support it could provide to improve the final product robustness.","PeriodicalId":9253,"journal":{"name":"British Journal of Pharmacy","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89676840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Solubility Enhancement for Dietheyldithiocarbamate-Zinc for Lung Cancer Treatment 提高二乙基二硫代氨基甲酸锌治疗肺癌的溶解度
Pub Date : 2022-10-18 DOI: 10.5920/bjpharm.1147
A. Kaya, Niusha Ansari-Fard, D. Alves, B. Arafat, H. Chichger, Mohammad Najlah
Diethyldithiocarbamate zinc (Zn(DDC)2), has shown promising antineoplastic effects against a wide variety of cancers. However, this application was hindered by its poor water solubility. Therefore, complexation with cyclodextrin was used to enhance the solubility. Five different concentrations of 2-hydroxyl beta-cyclodextrin (HP) and ether beta-cyclodextrin (SBE) were used. CD-Zn(DDC)2 solutions were freez-dried for further characterisation using DSC, TGA and FT-IR. The phase solubility study showed a significant water-solubility enchantment of  Zn(DDC)2, and the characterisation studies confirmed the formation of inclusion complexes CD-Zn(DDC)2. Overall, CDs have improved Zn(DDC)2 solubility significantly and showed a promising anticancer activity against lung cancer cells. Hence, CD-Zn(DDC)2 complexes have a great potential for further studies against cancer.    
二乙基二硫代氨基甲酸锌(Zn(DDC)2)已显示出对多种癌症有良好的抗肿瘤作用。然而,它的水溶性差阻碍了它的应用。因此,采用环糊精络合来提高溶解度。采用5种不同浓度的2-羟基-环糊精(HP)和醚-环糊精(SBE)。CD-Zn(DDC)2溶液被冷冻干燥,用DSC、TGA和FT-IR进一步表征。相溶解度研究表明Zn(DDC)2具有明显的水溶性增强,表征研究证实CD-Zn(DDC)2形成包合物。综上所述,CDs显著提高了Zn(DDC)2的溶解度,对肺癌细胞显示出良好的抗癌活性。因此,CD-Zn(DDC)2配合物具有进一步研究抗癌的巨大潜力。
{"title":"Solubility Enhancement for Dietheyldithiocarbamate-Zinc for Lung Cancer Treatment","authors":"A. Kaya, Niusha Ansari-Fard, D. Alves, B. Arafat, H. Chichger, Mohammad Najlah","doi":"10.5920/bjpharm.1147","DOIUrl":"https://doi.org/10.5920/bjpharm.1147","url":null,"abstract":"Diethyldithiocarbamate zinc (Zn(DDC)2), has shown promising antineoplastic effects against a wide variety of cancers. However, this application was hindered by its poor water solubility. Therefore, complexation with cyclodextrin was used to enhance the solubility. Five different concentrations of 2-hydroxyl beta-cyclodextrin (HP) and ether beta-cyclodextrin (SBE) were used. CD-Zn(DDC)2 solutions were freez-dried for further characterisation using DSC, TGA and FT-IR. The phase solubility study showed a significant water-solubility enchantment of  Zn(DDC)2, and the characterisation studies confirmed the formation of inclusion complexes CD-Zn(DDC)2. Overall, CDs have improved Zn(DDC)2 solubility significantly and showed a promising anticancer activity against lung cancer cells. Hence, CD-Zn(DDC)2 complexes have a great potential for further studies against cancer.    ","PeriodicalId":9253,"journal":{"name":"British Journal of Pharmacy","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87425494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Critical Material Attributes of HPMC on the Release of Gliclazide from Hydrophilic Matrix Tablets HPMC关键材料性质对亲水基质片中格列齐特释放的影响
Pub Date : 2022-10-10 DOI: 10.5920/bjpharm.1244
M. S. Qadir, Carsten Huettermann
The influence of HPMCviscosity and the degree of substitution hydroxypropyl level (DSHP) on therelease rate of gliclazide was examined. The increase in the HPMC viscosity ledto a significant decrease in the release rate. The second parameter, DSHP,showed a surprisingly high impact on the release rate with higher hydroxypropyllevels leading to a faster drug release. The results demonstrated the need forcontrol on both parameters for formulators of gliclazide tablets in order toensure a consistent drug release performance.
考察了羟丙基取代度(DSHP)和羟丙基粘度对格列齐特释放速率的影响。HPMC黏度的增加导致释放速率显著降低。第二个参数,DSHP,显示出惊人的高影响释放率,高羟丙基水平导致更快的药物释放。结果表明,为了保证格列齐特片的释药性能一致,需要对这两个参数进行控制。
{"title":"Impact of Critical Material Attributes of HPMC on the Release of Gliclazide from Hydrophilic Matrix Tablets","authors":"M. S. Qadir, Carsten Huettermann","doi":"10.5920/bjpharm.1244","DOIUrl":"https://doi.org/10.5920/bjpharm.1244","url":null,"abstract":"The influence of HPMCviscosity and the degree of substitution hydroxypropyl level (DSHP) on therelease rate of gliclazide was examined. The increase in the HPMC viscosity ledto a significant decrease in the release rate. The second parameter, DSHP,showed a surprisingly high impact on the release rate with higher hydroxypropyllevels leading to a faster drug release. The results demonstrated the need forcontrol on both parameters for formulators of gliclazide tablets in order toensure a consistent drug release performance.","PeriodicalId":9253,"journal":{"name":"British Journal of Pharmacy","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73030700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Evaluation of the Disintegrant Properties of Starches from Three Cultivars of Dioscorea rotundata (Poir) 3个圆形薯蓣品种淀粉崩解性能的比较评价
Pub Date : 2022-10-04 DOI: 10.5920/bjpharm.880
O. Akin-Ajani, Olamide I. Agbomeji, Oluwatoyin A. Odeku, U. Ahmadu
Poir starches from three cultivars (Lagos, Giwa, and Sule) were evaluated asexo-disintegrants (5 and 10%w/w) in paracetamol tablet formulations to determine whether the similarity in their physicochemical and material properties translates to performance in tablet formulation. The tablets were prepared by wet granulation and were evaluated for compressional properties (Heckel equation), mechanical strength (crushing strength and friability), and drug release (disintegration and dissolution times). Plastic deformation occurred in all tablets with rank order for the onset of plastic deformation Lagos>Giwa>Sule. An increase in the concentration of disintegrants in the tablets led to a decrease in mean yield pressure, total relative precompression density, and relative density at low pressure, but an increase in relative density at zero pressure. The crushing strength and disintegration times of the tablets were dependent on the disintegrants' concentration. All tablets passed the disintegration test (≤15min) with tablets containing the Sule cultivar producing the fastest disintegration (p<0.05). Tablets containing 10% of the Sule cultivar had the fastest release of paracetamol (t80=32.1min), though it failed the compendial standard for immediate release tablets (t80≤30min). Starches from the three cultivars despite their similar physicochemical and material properties exhibited different disintegrant properties and could find different applications as excipients in tablet formulations.
对3个品种(拉各斯、吉瓦和苏莱)的Poir淀粉在扑热息痛片剂中的抗溶出性(5%和10%w/w)进行了评价,以确定其理化性质和材料性质的相似性是否转化为片剂的性能。采用湿法造粒法制备片剂,并对片剂的压缩性能(Heckel方程)、机械强度(破碎强度和脆性)、药物释放度(崩解和溶出时间)进行评价。所有片剂均发生塑性变形,发生塑性变形的顺序为拉各斯>吉瓦>舒勒。随着崩解剂浓度的增加,片剂的平均屈服压力、总相对预压密度和低压条件下的相对密度降低,而零压条件下的相对密度增加。崩解剂的浓度对片剂的破碎强度和崩解次数有影响。所有片剂均通过崩解试验(≤15min),其中苏儿品种片剂崩解速度最快(p<0.05)。含10%的胶囊释放速度最快(t80=32.1min),但未达到药典即刻释放标准(t80≤30min)。尽管这三个品种的淀粉具有相似的理化性质和物质性质,但它们的崩解性质却不同,可以作为辅料在片剂配方中有不同的应用。
{"title":"Comparative Evaluation of the Disintegrant Properties of Starches from Three Cultivars of Dioscorea rotundata (Poir)","authors":"O. Akin-Ajani, Olamide I. Agbomeji, Oluwatoyin A. Odeku, U. Ahmadu","doi":"10.5920/bjpharm.880","DOIUrl":"https://doi.org/10.5920/bjpharm.880","url":null,"abstract":"Poir starches from three cultivars (Lagos, Giwa, and Sule) were evaluated asexo-disintegrants (5 and 10%w/w) in paracetamol tablet formulations to determine whether the similarity in their physicochemical and material properties translates to performance in tablet formulation. The tablets were prepared by wet granulation and were evaluated for compressional properties (Heckel equation), mechanical strength (crushing strength and friability), and drug release (disintegration and dissolution times). Plastic deformation occurred in all tablets with rank order for the onset of plastic deformation Lagos>Giwa>Sule. An increase in the concentration of disintegrants in the tablets led to a decrease in mean yield pressure, total relative precompression density, and relative density at low pressure, but an increase in relative density at zero pressure. The crushing strength and disintegration times of the tablets were dependent on the disintegrants' concentration. All tablets passed the disintegration test (≤15min) with tablets containing the Sule cultivar producing the fastest disintegration (p<0.05). Tablets containing 10% of the Sule cultivar had the fastest release of paracetamol (t80=32.1min), though it failed the compendial standard for immediate release tablets (t80≤30min). Starches from the three cultivars despite their similar physicochemical and material properties exhibited different disintegrant properties and could find different applications as excipients in tablet formulations.","PeriodicalId":9253,"journal":{"name":"British Journal of Pharmacy","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83047037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Hydrophobic Powders on the Tensile Strength of the Tablet 疏水粉末对片剂抗拉强度的影响
Pub Date : 2022-09-25 DOI: 10.5920/bjpharm.1162
Zoe Chu
Zoe Chu1,2, Christopher Windows-Yule¹, Ian Gabbott², Gavin Reynolds², Rachael Shinebaum² and Andy Ingram¹1. School of Chemical Engineering, University of Birmingham, Edgbaston, B15 2TT2. Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UKEmail: zhc906@student.bham.ac.ukIntroductionA tablet consists of the active pharmaceutical ingredients (API), and the other components, excipients. A tablet needs to withstand coating, packing and shipping stresses whilst maintaining the dissolution time; therefore, the tensile strength is of great importance. Currently, there is a lack of understanding on why excipients improve the bulk powder properties and the bonding mechanisms of the powder during compression. This makes tablet formulation development an inefficient trial-and-error process that is required for every new API (1). Literature has shown that the surface energy of the powders contributes a significant amount towards the tablet tensile strength. Hydrophobic powders have a lower surface energy (2) and are seen to disrupt this tablet strength (3,4).Experimental Aim and MethodThe aim was to investigate the impact of the hydrophobicity of excipient powders on tabletability of microcrystalline cellulose. This was done by mixing powders of varying hydrophobicity with MCC at varying mass fractions. There was focus on a lower mass fraction (0.02-0.1 m/m) with increasing increments of 0.02 m/m of added additive as well as gaining a global picture (0.2-1 m/m) with increments of 0.2 m/m.ResultsIt was found that at low mass fractions (0.02-0.4 m/m) of additive added the hydrophobic powders disrupted the tablet strength more compared to hydrophilic powders which could be attributed to the levels of surface energy of the additive. In contrast, at higher mass fractions (0.6-0.8 m/m), the surface energy is not as important and it is hypothesised that the deformation mechanisms of the additives governs the tablet strength.1. Reynolds GK, Campbell JI, Roberts RJ. A compressibility based model for predicting the tensile strength of directly compressed pharmaceutical powder mixtures. Int J Pharm [Internet]. 2017;531(1):215–24. Available from: http://dx.doi.org/10.1016/j.ijpharm.2017.08.0752. Sunkara D, Capece M. Influence of Material Properties on the Effectiveness of Glidants Used to Improve the Flowability of Cohesive Pharmaceutical Powders. AAPS PharmSciTech. 2018;19(4):1920–30. 3. Zuurman K, Maarschalk KVDV, Bolhuis GK. Effect of magnesium stearate on bonding and porosity expansion of tablets produced from materials with different consolidation properties. 1999;179:107–15. 4. Mishra SM, Rohera BD. Mechanics of tablet formation: a comparative evaluation of percolation theory with classical concepts. Pharm Dev Technol [Internet]. 2019;24(8):954–66. Available from: https://doi.org/10.1080/10837450.2019.1599913
Zoe Chu1、2、Christopher Windows-Yule 1、Ian Gabbott 2、Gavin Reynolds 2、Rachael Shinebaum 2和Andy Ingram 1。英国伯明翰大学化学工程学院,英国埃德巴斯顿b152tt2口服产品开发,制药技术与开发,运营,阿斯利康,麦克尔斯菲尔德,UKEmail: zhc906@student.bham.ac.ukIntroductionA片剂由活性药物成分(API),和其他成分,赋形剂组成。片剂需要承受涂层、包装和运输压力,同时保持溶解时间;因此,抗拉强度非常重要。目前,人们对辅料改善粉末散装性能的原因和粉末在压缩过程中的结合机制缺乏了解。这使得片剂配方的开发成为一个低效的试错过程,而每一个新的原料药都需要这种试错过程(1)。文献表明,粉末的表面能对片剂的抗拉强度有很大的影响。疏水粉末具有较低的表面能(2),并且被认为会破坏这种片剂强度(3,4)。实验目的与方法研究微晶纤维素辅料粉末的疏水性对其可溶性的影响。这是通过混合不同质量分数的不同疏水性粉末和MCC来完成的。当添加量增加0.02 m/m时,重点关注较低的质量分数(0.02-0.1 m/m);当添加量增加0.2 m/m时,重点关注整体图像(0.2-1 m/m)。结果在低质量分数(0.02 ~ 0.4 m/m)下,疏水粉末对片剂强度的影响大于亲水粉末,这与添加剂的表面能水平有关。相比之下,在较高的质量分数(0.6-0.8 m/m)下,表面能不那么重要,假设添加剂的变形机制决定了片剂的强度。雷诺兹GK,坎贝尔JI,罗伯茨RJ。基于可压缩性的预测直接压缩药物粉末混合物抗拉强度的模型。国际医药[互联网]。531(1): 215 - 2017; 24。可从:http://dx.doi.org/10.1016/j.ijpharm.2017.08.0752。Sunkara D, Capece M.材料性能对胶粘剂对药物粉末流动性的影响。aap PharmSciTech。2018; 19(4): 1920 - 30。3.Zuurman K, Maarschalk KVDV, Bolhuis GK。硬脂酸镁对不同固结性能材料制成的片剂粘结及孔隙膨胀的影响。1999; 179:107-15。4. [m],罗赫拉BD.片剂形成机制:渗流理论与经典概念的比较评价。]Pharm Dev technology [Internet]。2019; 24(8): 954 - 66。可从:https://doi.org/10.1080/10837450.2019.1599913获得
{"title":"Effect of Hydrophobic Powders on the Tensile Strength of the Tablet","authors":"Zoe Chu","doi":"10.5920/bjpharm.1162","DOIUrl":"https://doi.org/10.5920/bjpharm.1162","url":null,"abstract":"Zoe Chu1,2, Christopher Windows-Yule¹, Ian Gabbott², Gavin Reynolds², Rachael Shinebaum² and Andy Ingram¹1. School of Chemical Engineering, University of Birmingham, Edgbaston, B15 2TT2. Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UKEmail: zhc906@student.bham.ac.ukIntroductionA tablet consists of the active pharmaceutical ingredients (API), and the other components, excipients. A tablet needs to withstand coating, packing and shipping stresses whilst maintaining the dissolution time; therefore, the tensile strength is of great importance. Currently, there is a lack of understanding on why excipients improve the bulk powder properties and the bonding mechanisms of the powder during compression. This makes tablet formulation development an inefficient trial-and-error process that is required for every new API (1). Literature has shown that the surface energy of the powders contributes a significant amount towards the tablet tensile strength. Hydrophobic powders have a lower surface energy (2) and are seen to disrupt this tablet strength (3,4).Experimental Aim and MethodThe aim was to investigate the impact of the hydrophobicity of excipient powders on tabletability of microcrystalline cellulose. This was done by mixing powders of varying hydrophobicity with MCC at varying mass fractions. There was focus on a lower mass fraction (0.02-0.1 m/m) with increasing increments of 0.02 m/m of added additive as well as gaining a global picture (0.2-1 m/m) with increments of 0.2 m/m.ResultsIt was found that at low mass fractions (0.02-0.4 m/m) of additive added the hydrophobic powders disrupted the tablet strength more compared to hydrophilic powders which could be attributed to the levels of surface energy of the additive. In contrast, at higher mass fractions (0.6-0.8 m/m), the surface energy is not as important and it is hypothesised that the deformation mechanisms of the additives governs the tablet strength.1. Reynolds GK, Campbell JI, Roberts RJ. A compressibility based model for predicting the tensile strength of directly compressed pharmaceutical powder mixtures. Int J Pharm [Internet]. 2017;531(1):215–24. Available from: http://dx.doi.org/10.1016/j.ijpharm.2017.08.0752. Sunkara D, Capece M. Influence of Material Properties on the Effectiveness of Glidants Used to Improve the Flowability of Cohesive Pharmaceutical Powders. AAPS PharmSciTech. 2018;19(4):1920–30. 3. Zuurman K, Maarschalk KVDV, Bolhuis GK. Effect of magnesium stearate on bonding and porosity expansion of tablets produced from materials with different consolidation properties. 1999;179:107–15. 4. Mishra SM, Rohera BD. Mechanics of tablet formation: a comparative evaluation of percolation theory with classical concepts. Pharm Dev Technol [Internet]. 2019;24(8):954–66. Available from: https://doi.org/10.1080/10837450.2019.1599913","PeriodicalId":9253,"journal":{"name":"British Journal of Pharmacy","volume":"59 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89488333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Process Parameters on the critical attributes of the Liposomal formulations 工艺参数对脂质体制剂关键属性的影响
Pub Date : 2022-07-26 DOI: 10.5920/bjpharm.1172
Bayan Abu Ras, Youssef Haggag, M. Isreb, M. El Tanani
This study investigate the effect of processparameters on the size, distribution, zeta potential  and loading efficiency for the co-delivery of liposomalformulation of Ran-RCC1 inhibitory peptide (RANIP) and doxorubicin (DOX) tobreast cancer. The results showthat drug concentration, pH and ultrasound intensity are all critical factors tocontrol the attributes of the liposomes.
本研究探讨了工艺参数对rani - rcc1抑制肽(RANIP)和阿霉素(DOX)脂质体制剂对乳腺癌共递送的大小、分布、zeta电位和负载效率的影响。结果表明,药物浓度、pH和超声强度是控制脂质体属性的关键因素。
{"title":"Effect of Process Parameters on the critical attributes of the Liposomal formulations","authors":"Bayan Abu Ras, Youssef Haggag, M. Isreb, M. El Tanani","doi":"10.5920/bjpharm.1172","DOIUrl":"https://doi.org/10.5920/bjpharm.1172","url":null,"abstract":"This study investigate the effect of processparameters on the size, distribution, zeta potential  and loading efficiency for the co-delivery of liposomalformulation of Ran-RCC1 inhibitory peptide (RANIP) and doxorubicin (DOX) tobreast cancer. The results showthat drug concentration, pH and ultrasound intensity are all critical factors tocontrol the attributes of the liposomes.","PeriodicalId":9253,"journal":{"name":"British Journal of Pharmacy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77072129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Formulation of an implantable device from mini tablets-in-PCL cylinders for sustained delivery of a hydrophobic drug 一种用于持续递送疏水药物的微型pcl瓶片可植入装置的配方
Pub Date : 2022-07-19 DOI: 10.5920/bjpharm.1153
Camila J Picco, Peter E. McKenna, E. Larrañeta
Implantable drug delivery systems are presented as a potential alternative to current treatments of chronic conditions. The aim of this work was to formulate a subcutaneous implantable device made with prefabricated poly(caprolactone) (PCL) cylinders, loaded with olanzapine (OLZ) as a model drug and cyclodextrin in a mass ratio of 1:1. The final formulation was characterized using optical microscopy, infrared spectroscopy, thermal analysis, and X-ray diffraction. The proposed device was successfully fabricated and demonstrated ability to control drug release for 60 days. With continued development, these novel implants could be an alternative to currently available treatments for schizophrenia.
植入式药物输送系统是目前慢性疾病治疗的潜在替代方案。本研究以预制聚己内酯(PCL)圆柱体为材料,以奥氮平(OLZ)为模型药物,以环糊精为质量比,制备一种皮下植入装置。用光学显微镜、红外光谱、热分析和x射线衍射对最终配方进行了表征。所提出的装置已成功制造,并证明能够控制药物释放60天。随着不断的发展,这些新型植入物可能成为目前可用的精神分裂症治疗方法的替代方案。
{"title":"Formulation of an implantable device from mini tablets-in-PCL cylinders for sustained delivery of a hydrophobic drug","authors":"Camila J Picco, Peter E. McKenna, E. Larrañeta","doi":"10.5920/bjpharm.1153","DOIUrl":"https://doi.org/10.5920/bjpharm.1153","url":null,"abstract":"Implantable drug delivery systems are presented as a potential alternative to current treatments of chronic conditions. The aim of this work was to formulate a subcutaneous implantable device made with prefabricated poly(caprolactone) (PCL) cylinders, loaded with olanzapine (OLZ) as a model drug and cyclodextrin in a mass ratio of 1:1. The final formulation was characterized using optical microscopy, infrared spectroscopy, thermal analysis, and X-ray diffraction. The proposed device was successfully fabricated and demonstrated ability to control drug release for 60 days. With continued development, these novel implants could be an alternative to currently available treatments for schizophrenia.","PeriodicalId":9253,"journal":{"name":"British Journal of Pharmacy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87942426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and characterization of injectable depot forming thermoresponsive hydrogel for the sustained intrascleral delivery of Sunitinib Hollow microneedles for intrascleral drug delivery 用于舒尼替尼空心微针持续肌内给药的可注射储库形成热响应水凝胶的研制和表征
Pub Date : 2022-07-18 DOI: 10.5920/bjpharm.1175
Shilpkala Gade, E. Larrañeta, R. Donnelly, R. Vanrell, C. A. ALVAREZ LORENZO, R. Thakur
Age-related macular degeneration (AMD) is a potentially blinding posterior segment disease; inflammatory responses and subretinal drusen formation lead to leaky blood vessels. The current treatment method involves intravitreal injections of anti-VEGF agents, which is highly invasive and requires frequent injections administered by trained personnel. Periocular injections such as trans-/intra-scleral injections would provide a minimally invasive treatment option. The sclera is the outermost protective layer occupying 5/6th of the ocular globe. Owing to its avascular nature and self-healing ability, sclera could be the potential space for the delivery of depot forming long-acting formulations. This project focuses on the development of chitosan grafted poly(n-isopropylacrylamide) (Cs-g-PNIPAAm) gel for the sustained intrascleral delivery of small molecular weight, multiple tyrosine kinase inhibitor Sunitinib malate.
年龄相关性黄斑变性(AMD)是一种潜在的致盲后段疾病;炎症反应和视网膜下积水的形成导致血管渗漏。目前的治疗方法包括玻璃体内注射抗vegf药物,这是高度侵入性的,需要由训练有素的人员经常注射。眼周注射如经/巩膜内注射将提供一种微创治疗选择。巩膜是眼球最外层的保护层,占眼球的5/6。由于其无血管性质和自我修复能力,巩膜可能是输送长效制剂的潜在空间。本项目重点开发壳聚糖接枝聚(n-异丙基丙烯酰胺)(Cs-g-PNIPAAm)凝胶,用于小分子量、多种酪氨酸激酶抑制剂苹果酸舒尼替尼的持续囊内递送。
{"title":"Development and characterization of injectable depot forming thermoresponsive hydrogel for the sustained intrascleral delivery of Sunitinib Hollow microneedles for intrascleral drug delivery","authors":"Shilpkala Gade, E. Larrañeta, R. Donnelly, R. Vanrell, C. A. ALVAREZ LORENZO, R. Thakur","doi":"10.5920/bjpharm.1175","DOIUrl":"https://doi.org/10.5920/bjpharm.1175","url":null,"abstract":"Age-related macular degeneration (AMD) is a potentially blinding posterior segment disease; inflammatory responses and subretinal drusen formation lead to leaky blood vessels. The current treatment method involves intravitreal injections of anti-VEGF agents, which is highly invasive and requires frequent injections administered by trained personnel. Periocular injections such as trans-/intra-scleral injections would provide a minimally invasive treatment option. The sclera is the outermost protective layer occupying 5/6th of the ocular globe. Owing to its avascular nature and self-healing ability, sclera could be the potential space for the delivery of depot forming long-acting formulations. This project focuses on the development of chitosan grafted poly(n-isopropylacrylamide) (Cs-g-PNIPAAm) gel for the sustained intrascleral delivery of small molecular weight, multiple tyrosine kinase inhibitor Sunitinib malate.","PeriodicalId":9253,"journal":{"name":"British Journal of Pharmacy","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81432122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Solubility measurement of poorly soluble drugs in fasted state simulated intestinal fluid 难溶性药物在空腹模拟肠液中的溶解度测定
Pub Date : 2022-07-15 DOI: 10.5920/bjpharm.1075
Zoe McKinnon, Hannah Batchelor, I. Khadra, Gavin W. Halbert
Adequatedrug solubility in the gastrointestinal tract is essential for systemic therapyof orally administered medications. To carry out research on the solubility ofpoorly soluble drugs in vitro, simulated intestinal fluid (SIF) is usedin place of human intestinal fluid (HIF). However, typical SIF reflects averagecompositions of HIF rather than the full range of compositions previouslyreported. This study examines a new suite of SIF media (based on variabilityobserved in HIF) to explore the range of solubility of four poorly soluble drugs(Naproxen, Indomethacin, Phenytoin and Tadalafil) in the fasted state.
药物在胃肠道的充分溶解度对于口服药物的全身治疗至关重要。为了研究难溶性药物的体外溶解度,采用模拟肠液(SIF)代替人肠液(HIF)。然而,典型的SIF反映了HIF的平均成分,而不是先前报道的全部成分。本研究考察了一套新的SIF培养基(基于HIF观察到的变异性),以探索四种难溶性药物(萘普生、吲哚美辛、苯妥英和他达拉非)在禁食状态下的溶解度范围。
{"title":"Solubility measurement of poorly soluble drugs in fasted state simulated intestinal fluid","authors":"Zoe McKinnon, Hannah Batchelor, I. Khadra, Gavin W. Halbert","doi":"10.5920/bjpharm.1075","DOIUrl":"https://doi.org/10.5920/bjpharm.1075","url":null,"abstract":"Adequatedrug solubility in the gastrointestinal tract is essential for systemic therapyof orally administered medications. To carry out research on the solubility ofpoorly soluble drugs in vitro, simulated intestinal fluid (SIF) is usedin place of human intestinal fluid (HIF). However, typical SIF reflects averagecompositions of HIF rather than the full range of compositions previouslyreported. This study examines a new suite of SIF media (based on variabilityobserved in HIF) to explore the range of solubility of four poorly soluble drugs(Naproxen, Indomethacin, Phenytoin and Tadalafil) in the fasted state.","PeriodicalId":9253,"journal":{"name":"British Journal of Pharmacy","volume":"119 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79415204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
British Journal of Pharmacy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1